URCH study foresees more pharma mega-mergers
Pfizer's merger with fellow US drug major Wyeth (Marketletters pasim) will bring significant change to the pharmaceutical industry and may result in more large deals before the end of the year, suggests a new report. "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 - Critical success factors for competing in a consolidating market" from URCH Publishing, states that a number of major pharmaceutical players will follow in the footsteps of Pfizer and enter into significant M&A transactions.
"2009 is set to redefine the structure and dynamics of the pharmaceutical industry in a way not seen since the year 2000," says Steve Seget, the report's author.
The 111-page study, available from URCH Publishing at: http://tinyurl.com/dz2v7m, says that it is likely that the mega-M&A wave started by the three deals agreed in the first quarter of 2009 is not yet finished, with possibly three more mega-deals to go, which will see movement in the top ten pharmaceutical company list.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze